Shopping Cart (0)
My Account

Shopping Cart
3 for 2 Offer SELECTBIO Conferences Innovations in Microfluidics 2024: Rapid Prototyping, 3D-PrintingLiquid Biopsy 2024: Technologies & ApplicationsCirculating Biomarkers and Extracellular Vesicles Europe 2024Point-of-Care, Biosensors and Rapid Dx Europe 2024Organoids and Spheroids Europe 2024ePoster Award Prize

The Past, Present, and Future of Cell-Free Nucleic Acids as a Liquid Biopsy in Precision Medicine



Qing Kang, Senior Scientist, Syros Pharmaceuticals, Inc.

Qing Kang, Ph.D., has been in her current role as a Senior Scientist in Translational Medicine at Syros Pharmaceuticals, Inc. since March, 2018. Previously she served as a Scientist at Progenity, Inc. from May 2017 to March 2018, where she was responsible for research and development activities associated with oncology and liver disease biomarker discovery and validation, with a focus of utilizing next generation sequencing based technologies to develop diagnostic tests that influence clinical decisions. Prior to joining Progenity she was a research fellow in Dr. Muneesh Tewari’s laboratory at the University of Michigan, where she led a multidisciplinary team to study circulating tumor DNA both in blood and urine as a non-invasive approach to detect and monitor cancer patients. She is also a group member of Cancer Moonshot Blood Profiling Atlas Program since October, 2016. She received a B. E. in Bioengineering from China Pharmaceutical University and a Ph.D. in Molecular Biology and Genetics from Indiana University Bloomington.

Qing Kang Image